三磷酸腺苷法肿瘤药敏试验在乳腺癌中的临床应用

目的:采用三磷酸腺苷法肿瘤药敏试验(ATP-TCA)对乳腺癌组织标本进行试验,为个体化化疗选择提供客观依据。方法:75例乳腺癌新鲜标本行原代培养后,6种化疗药物用该方法进行试验。结果:所有标本均顺利完成试验,单药强敏感率顺序为THP(25.33%)、E-ADM(21.33%)、DTX(20.00%)、MTX(13.33%)、gemcitabine(12.00%),5-Fu(6.67%)。不同乳腺癌不但对同一种化疗药物的敏感度有明显差异(P<0.05),而且对不同药物的敏感程度也具有统计学差异(P<0.05)。随访3年可见,治疗组复发转移率低于对照组,也具统计学差异(P<0.05)。结论:三磷酸腺苷法可方便有效检测乳腺癌个体的敏感化疗药物,在临床应用可提高乳腺癌化疗效果,为乳腺癌的临床个体化化疗提供重要的客观指导作用。

Adenosine triphosphate based tumour chemosensitivity assay in breast carcinoma of clinical research

Objective:To investigate the heterogeneity of chemosensitivity in breast carcinoma using adenosine triphosphate based tumour chemosensitivity assay(ATP-TCA) and the feasibility of individual chemotherapy.Methods:ATP-TCA was used to determine the effect of 6 single drugs in surgical specimens from 75 patients with breast carcinoma.And 60 patients with breast carcinoma were used as matched control group.Results:All above these specimens were detected successfully.The sensitivity of six drugs was 25.33% for THP,21.33% for E-ADM,20.00% for DTX,13.33% for MTX,12.00% for gemcitabine,6.67% for 5-Fu in these specimens respectively.There were the heterogeneity of the in vitro chemosensitivity in breast carcinoma and had statistical significance(P < 0.05).After three years followed up,the relapse rate of therapy group was lower than that of the matched control group with statistical significance(P < 0.05).Conclusion:The use of the ATP-TCA may provide a method of selecting appropriate anti-cancer drugs of breast carcinoma in chemotherapy of individualization.